SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Revolutions Medical Corporation (OTCBB: RMCP) $0.49. Announced Monday after market close detailed performance and aesthetic improvements to its flagship Rev Vac syringe, and debuted a highly informative product demonstration video.
"We will unveil the long-anticipated enhanced design of the Rev Vac safety syringe on our website tonight," stated Company CEO Ron Wheet. "The improvements increase substantially the readability of the fluid levels and the accuracy of the fluid draw. A distinctive color scheme makes the Rev Vac syringe easily identifiable. Simple to read pictograms on each packet insert allow for reduced training needs while improving correct usage. Combined, these feature enhancements dramatically escalate our competitive advantage in the space, and ensure a product that not only costs less, but significantly outperforms many established products.
"And with our new animated demonstration video, we now have an engaging and educational resource that will serve as both an exceptional sales piece and an unparalleled training tool. At time of product launch, we will feature a dynamic multi-media marketing platform that will further set Revolutions Medical apart as the leading safety syringe company."
The Rev Vac safety syringe received FDA 510K clearance earlier this year; this redesign does not impact that clearance.
What They Do: Revolution Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.
GENova Biotherapeutics (OTCBB: CVBP) $0.42. Annound Monday after market close that it has signed a collaboration agreement with Bridge Bioresearch Plc., an international drug development and discovery company that focuses on metabolic disorders. The two biotechnology drug acquisition companies plan to leverage each others' scientific findings and industry contacts for mutual gain.
What They Do: GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/. SCR has been compensated up to three thousand five hundred dollars by a third party APS for its services with regards to Revolutions Medical Corporation.
